Get the Stockscreener App
20.73
2.22%
0.45
Enliven Therapeutics Inc stock is traded at $20.73, with a volume of 85,282.
It is up +2.22% in the last 24 hours and down -5.34% over the past month.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
See More
Previous Close:
$20.28
Open:
$20.23
24h Volume:
85,282
Relative Volume:
0.39
Market Cap:
$1.01B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-10.97
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
-1.38%
1M Performance:
-5.34%
6M Performance:
-10.14%
1Y Performance:
+18.19%
1-Day Range:
$20.18
$21.18
1-Week Range:
$19.98
$22.21
52-Week Range:
$15.96
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
20.73 | 1.01B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
513.86 | 130.83B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.53 | 73.16B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
617.64 | 37.89B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.13 | 32.28B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
265.95 | 28.52B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
Enliven Therapeutics Inc Stock (ELVN) Latest News
Decoding Enliven Therapeutics Inc (ELVN): A Strategic SWOT Insig - GuruFocus.com
Enliven grew fourth-quarter R&D spending with trials underway - BizWest
Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline - Value the Markets
Enliven Therapeutics Reports 2024 Financial Results - TipRanks
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - Citizentribune
Enliven Therapeutics Inc. (ELVN) reports earnings - Quartz
Enliven Therapeutics Q4 Operating Expenses USD 26.896 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
ENLIVEN THERAPEUTICS Earnings Results: $ELVN Reports Quarterly Earnings - Nasdaq
Enliven Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (ELVN) Enliven Therapeutics Posts Q4 Loss $-0.46 Per Share -March 13, 2025 at 04:12 pm EDT - Marketscreener.com
Enliven Therapeutics Secures 3-Year Runway with $313M War Chest, Advances Cancer Drug Pipeline - StockTitan
Enliven Therapeutics COO Anish Patel sells $142,936 in stock - Investing.com
(ELVN) Investment Analysis and Advice - Stock Traders Daily
Enliven Therapeutics (ELVN) Projected to Post Quarterly Earnings on Thursday - Defense World
New York State Common Retirement Fund Sells 2,488 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics CFO Sells Shares - TradingView
Enliven Therapeutics CFO sells $22,524 in stock - MSN
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Longview News-Journal
Can Enliven Therapeutics Impress Investors at the Upcoming TD Cowen Healthcare Conference? - StockTitan
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap DownHere's Why - MarketBeat
(ELVN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in Stock - MarketBeat
Enliven Therapeutics COO Anish Patel sells $146,205 in stock - MSN
Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat
Enliven Therapeutics COO Anish Patel sells $146,205 in stock By Investing.com - Investing.com South Africa
Trend Tracker for (ELVN) - Stock Traders Daily
Enliven Therapeutics: Promising Innovations in Tyrosine Kinase Inhibitors and Strategic Growth Plans Justify Buy Rating - TipRanks
SG Americas Securities LLC Increases Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Strong Buy Recommendation for Enliven Therapeutics Due to ELVN-001’s High Selectivity and Promising Clinical Data - TipRanks
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares - MarketBeat
Enliven Therapeutics CFO sells $70,177 in stock - MSN
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Objective long/short (ELVN) Report - Stock Traders Daily
Enliven Therapeutics (NASDAQ:ELVN) Shares Up 11.3%Here's Why - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Barclays PLC Acquires 42,012 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $524,706.00 in Stock - MarketBeat
Anish Patel, COO of Enliven Therapeutics, sells $685,868 in stock By Investing.com - Investing.com Nigeria
Anish Patel, COO of Enliven Therapeutics, sells $685,868 in stock - Investing.com
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 9.8%Time to Sell? - MarketBeat
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.16%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):